Trial reportPloS one2013
Long-term follow-up observation of the safety, immunogenicity, and effectiveness of Gardasil™ in adult women.
Trial report in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00090220 (Safety, Immunogenicity, and Efficacy of Gardasil), which is not on this map. Cited by 48 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety, Immunogenicity, and Efficacy of Gardasil (V501 (Human Papilloma Virus [Types 6, 11, 16, 18] Recombinant Vaccine) in Mid-Adult Women - The FUTURE III (Females United to Unilaterally Reduce Endo/Ectocervical Cancer) Study
Who cites it
48 citing papers in PubMed, 9 syntheses or guidelines pooled it, 82 citations in OpenAlex.
- Impact of human papillomavirus vaccines in the reduction of infection, precursor lesions, and cervical cancer: A systematic literature review.Human vaccines & immunotherapeutics · 2025Pooled it
- Human papillomavirus (HPV) vaccination for the prevention of cervical cancer and other HPV-related diseases: a network meta-analysis.The Cochrane database of systematic reviews · 2025Pooled it
- Pooled it
- Role of human papillomavirus (HPV) vaccination on HPV infection and recurrence of HPV related disease after local surgical treatment: systematic review and meta-analysis.BMJ (Clinical research ed.) · 2022Pooled it
- Updated clinical guideline for human papillomavirus vaccine: the Korean Society of Gynecologic Oncology guidelines.Journal of gynecologic oncology · 2021Guideline
- Barriers to Human Papillomavirus Vaccine Uptake Among Racial/Ethnic Minorities: a Systematic Review.Journal of racial and ethnic health disparities · 2021Pooled it
- Clinical guideline for 9-valent HPV vaccine: Korean Society of Gynecologic Oncology Guideline.Journal of gynecologic oncology · 2019Guideline
- Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.The Cochrane database of systematic reviews · 2018Pooled it
- Safety of Human Papillomavirus 9-Valent Vaccine: A Meta-Analysis of Randomized Trials.Journal of immunology research · 2017Pooled it
- Evaluation of the immunogenicity of the quadrivalent HPV vaccine using 2 versus 3 doses at month 21: An epidemiological surveillance mechanism for alternate vaccination schemes.Human vaccines & immunotherapeutics · 2016Trial
- Ferritin nanoparticles displaying rift valley fever virus glycoprotein elicit potent dendritic cell activation in vitro.Virology journal · 2026Article
- Clinical and economic impact of school-based nonavalent human papillomavirus vaccination in females in Malaysia.Singapore medical journal · 2026Article
- Evaluating Now I Know mHealth intervention promoting HPV vaccine completion among young women attending federally supported clinics.Cancer causes & control : CCC · 2025Article
- Real-world safety of HPV vaccines over 18 y: A comprehensive analysis of U.S. VAERS reports.Human vaccines & immunotherapeutics · 2025Article
- Influence of Pre-Vaccination HPV Status on Vaccine Effectiveness Among Chinese Women: A Multicenter Cross-Sectional Study.Cancer reports (Hoboken, N.J.) · 2025Article
- Vaccines in Dermatology-Present and Future: A Review.Vaccines · 2025Review
- The Non-inferiority of Human Papillomavirus Vaccine Immunogenicity Among Women Over 26 Years: A Systematic Review.Cureus · 2024Review
- Virus-like particles in poultry disease: an approach to effective and safe vaccination.Frontiers in veterinary science · 2024Review
- Primary care Providers' approaches to cervical cancer screening in Muslim females.Preventive medicine reports · 2023Article
- Human Papillomavirus Vaccine Impact and Effectiveness in Six High-Risk Populations: A Systematic Literature Review.Vaccines · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevious analyses from a randomized trial in women aged 24-45 have shown the quadrivalent HPV vaccine to be efficacious in the prevention of infection, cervical intraepithelial neoplasia (CIN) and external genital lesions (EGL) related to HPV 6/11/16/18 through 4 years. In this report we present long term follow-up data on the efficacy, safety and immunogenicity of the quadrivalent HPV vaccine in adult women.
methodsFollow-up data are from a study being conducted in 5 sites in Colombia designed to evaluate the long-term immunogenicity, effectiveness, and safety of the qHPV vaccine in women who were vaccinated at 24 to 45 years of age (in the original vaccine group during the base study [n = 684]) or 29 to 50 years of age (in the original placebo group during the base study [n = 651]). This analysis summarizes data collected as of the year 6 post-vaccination visit relative to day 1 of the base study (median follow-up of 6.26 years) from both the original base study and the Colombian follow-up.
resultsThere were no cases of HPV 6/11/16/18-related CIN or EGL during the extended follow-up phase in the per-protocol population. Immunogenicity persists against vaccine-related HPV types, and no evidence of HPV type replacement has been observed. No new serious adverse experiences have been reported.
conclusionsVaccination with qHPV vaccine provides generally safe and effective protection from HPV 6-, 11-, 16-, and 18-related genital warts and cervical dysplasia through 6 years following administration to 24-45 year-old women.
trial registrationClinicaltrials.govNCT00090220.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.